News & Insights
Analysis and perspectives on pharmaceutical pricing, market access, IRP, MFN policy, and AI-powered pricing tools.
Stay up to date with the latest developments in pharmaceutical pricing policy, including GENEROUS, MFN, and International Reference Pricing.
Introducing SyMAP 2.0: From Pricing Simulation to Pricing Strategy
SyMAP 2.0 is here, our biggest release yet. Reference pricing and US MFN now run as one simulation, the voluntary agreements get a deal designer…
The Art of the MFN Deal: What the CEA’s $600 Billion Report Means for Manufacturers
Policy Analysis The White House Council of Economic Advisers has finally put a number on Most Favored Nation drug pricing: close to $600 billion over…
Introducing SyMAP MFN: GENEROUS, GLOBE and GUARD in One Model
GENEROUS, GLOBE and GUARD each work differently and land on the same portfolio. SyMAP MFN runs all three on one set of products, prices and…
Symaptics at the World EPA Congress 2026 – Amsterdam, 3–4 March
The Symaptics team will be at the World Evidence, Pricing and Access (EPA) Congress in Amsterdam on 3–4 March 2026, Europe’s largest congress for market…
MFN and the Shift of Risk for Ex-US Markets
Global StrategyRosemarie Delaney PhD•February 2026•6 min readAlthough MFN policies are designed for the US, they shift pricing and policy risk onto ex-US health systems, turning…
Redefining Ex-US Success in an MFN World
Global StrategyRosemarie Delaney PhD•February 2026•5 min readIn an MFN-driven pricing environment, ex-US success is no longer defined by rapid launch and broad footprint, but by…
The End of Two Silos: Why Pharmaceutical Pricing Is Now a Single Global Challenge
Pricing Strategy Rosemarie Delaney PhD • January 2026 • 8 min read For decades, pharmaceutical pricing strategy has operated in two largely separate worlds. U.S.…
The Fine Print: Three Details in GLOBE & GUARD That Could Reshape Your MFN Strategy
Deep Dive Beyond the headlines, the GLOBE and GUARD proposed rules contain regulatory nuances that most coverage has overlooked. These details aren’t bugs—they’re features with…
Decoding GLOBE & GUARD: Medicare’s New MFN Models
Policy Analysis Chris McDonald PhD • January 2026 • 10 min read In December 2025, the CMS Innovation Center released proposed rules for two models—GLOBE…
GENEROUS: MFN Comes to Medicaid
Policy Analysis How CMS is turning international reference pricing into guaranteed net prices for state drug programs Chris McDonald PhD • November 2025 • 5…
Stay Updated
Get in touch to learn more about our AI-powered pharmaceutical pricing tools and stay informed on the latest policy developments.